Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer.
10.3857/jkstro.2011.29.1.20
- Author:
Sang Jun BYUN
1
;
Jin Hee KIM
;
Ok Bae KIM
;
Hong Suk SONG
Author Information
1. Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. jhkim@dsmc.or.kr
- Publication Type:Original Article
- Keywords:
Esophageal cancer;
Concurrent chemoradiotherapy;
Survival rate;
Prognostic factor;
Failure
- MeSH:
Chemoradiotherapy;
Cisplatin;
Disease Progression;
Disease-Free Survival;
Esophageal Neoplasms;
Female;
Fluorouracil;
Follow-Up Studies;
Hemoglobins;
Humans;
Male;
Multivariate Analysis;
Neoplasm Metastasis;
Recurrence;
Retrospective Studies;
Smoke;
Smoking;
Survival Rate;
Treatment Failure
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2011;29(1):20-27
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was designed to evaluate the results of local control, survival rate, prognostic factors, and failure pattern in locally advanced esophageal cancer. MATERIALS AND METHODS: We retrospectively studied 50 patients with locally advanced esophageal cancer treated with concurrent chemoradiotherapy at Keimyung University Dongsan Medical Center from June of 1999 to August of 2008. Seven patients with inappropriate data were excluded, and 43 patients were analyzed. There were 39 males and four female patients ranging in age from 43 to 78 years (median, 63 years). There were seven patients with stage IIA and 36 with stage III. Irradiation from 46 Gy to 63 Gy (median, 54 Gy) was carried out 5 days per week, 1.8 Gy once a day. There were eight patients with neo-adjuvant chemotherapy, and we mostly used 5-fluorouracil, cisplatin with 3 cycles for concurrent chemotherapy. The range of follow up periods was from 2 to 82 months (median, 15.5). RESULTS: There were nine patients that exhibited a complete response, 23 that exhibited a partial response, 9 that exhibited no response, and 2 that exhibited disease progression. The median survival time was 15 months. Two-year and 5-year survival rates were 36.5% and 17.3%, respectively. Two-year and 5-year disease-free survival rates were 32.4% and 16%, respectively. Treatment failure occurred in 22 patients (51.2%). Patterns of failure were categorized as local failure in 18 patients and distant metastasis in four patients. In a univariate analysis for prognostic factors related to overall survival and disease-free survival, the hemoglobin levels during chemoradiotherapy (> or =12 vs. <12, p=0.02/p=0.1) and the response to the treatments (CR/PR vs. NR/PD, p=0.002/p<0.0001) were statistically significant. In a multivariate analysis, only response to the treatments was revealed to be statistically significant. There was no statistical significance associated with patient age, gender, disease stage, T-stage, smoking history, tumor location, or neo-adjuvant chemotherapy. CONCLUSION: Our survival rate was similar to those of other institutions. Local recurrence was the main reason for failure. It is suggested that further prospective studies should be performed to improve local control.
